26 October 2018 : Original article
Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression
Faouzi Saliba BDF 1*, Lutz Fischer BDF 2, Paolo de Simone BDF 3, Peter Bernhardt CDF 4, Giovanni Bader CDF 4, John Fung BDF 5DOI: 10.12659/AOT.911030
Ann Transplant 2018; 23:751-757
Supplementary Table 1 First major adverse cardiac events to month 24, by MedDRA preferred term, according to treatment group (ITT population).
| EVR/rTAC N=245 | TAC Elimination N=231 | TAC Control N=243 | |
|---|---|---|---|
| Acute myocardial infarction | 1 | 0 | 2 |
| Angina pectoris | 1 | 1 | 4 |
| Angina unstable | 1 | 0 | 0 |
| Cardiac failure | 2 | 0 | 4 |
| Cardiac failure congestive | 0 | 1 | 1 |
| Coronary artery arteriosclerosis | 1 | 0 | 0 |
| Coronary artery disease | 2 | 0 | 3 |
| Coronary artery insufficiency | 0 | 1 | 0 |
| Ischemic stroke | 0 | 0 | 1 |
| Myocardial infarction | 0 | 1 | 0 |
| Myocardial ischemia | 1 | 0 | 1 |
| Pulmonary edema | 1 | 0 | 0 |
| Sudden death | 0 | 1 | 1 |